Joe Schmidt’s Post

Co-Founder and Member of the Board of Directors

Congratulations to the team at Direct Biologics for breaking new ground with this publication! https://lnkd.in/g9vzzNMw #Innovation #Technology #Future #ARDS #Research

Direct Biologics Announces Publication of Significant Survival Benefit with ExoFlo™ in its Phase 2 Randomized Controlled Clinical Trial in the Journal CHEST | Direct Biologics

https://directbiologics.com

6 Comments

Nikki Strassner

Sales Account Manager @ BoneBank Allografts | New Business Development, Orthopedics, regenerative medicine

Wow! That's super exciting for you and your team. Congrats to you all.

1 Reaction

Richard Bligh

CEO @ Dr. Bligh LLC | Founder

Very exciting news and a life saver for patients with ARDS.

1 Reaction

Manpreet Bains, PhD

Biotech Enthusiast | Business Development Professional | Experienced Immunologist | Expert in DNA, RNA, CRISPR and Viral Vectors Therapeutics

Congratulations to Joe, Tim and the Direct Biologics Team!

2 Reactions

Jordan VanGilder

Sales Executive | Pharmaceutical Track & Trace | Serialization & DSCSA Compliance

Congrats Direct Biologics Team!

1 Reaction

Paula Blonski

President-ARDS Alliance, Inc.-Sr. Manager, Insurance Risk and Loss Control. Opinions are my own

Congratulations!!

1 Reaction

Dean Johnson

Managing Partner at Verity Medical LLC / Advisor / Consultant

Congratulations Joe!

1 Reaction

See more comments

To view or add a comment, sign in

More Relevant Posts

Joe Schmidt

Co-Founder and Member of the Board of Directors
1w
Report this post
Dr. Richard Bligh has recently published a land mark study titled “Safety and Efficacy of Bone Marrow Mesenchymal Stem Cell Extacellular Vesicles in Long COVID Patients: A Case Report”. The significance of this study reminds me of an Einstein Quote, “Innovative spirits have always met opposition from mediocre minds.” Dr. Bligh has looked outside BIG PHARMA to offer his patients a safe and efficacious treatment for a condition affecting millions worldwide. He deserves to be applauded and his findings confirmed with class one data so his innovative treatment will become the standard of care!

Richard Bligh

CEO @ Dr. Bligh LLC | Founder
1w

Long COVID is a challenge to treat and many of us are seeing patients who are having long term disabilities. Just wanted to share our recent article that outlines the use of Extracellular Vesicles in Long COVID patients with excellent results.

1 Comment
Like Comment
To view or add a comment, sign in
Joe Schmidt

Co-Founder and Member of the Board of Directors
2mo
Report this post
Congratulations Katie! I am very proud of you!!
Katie Schmidt

Hello, I'm Katie Schmidt, recent graduate from the University of Missouri with a Bachelor of Arts & Science in political science. Excited to embark on my journey at SLU Law, focusing on corporate law. Let's connect!
2mo Edited

Excited to announce that I've graduated cum laude from the University of Missouri with a Bachelor in Arts and Sciences in Political Science, earning departmental honors along the way! Grateful for the support and looking forward to attending SLU Law in the fall!
10 Comments
Like Comment
To view or add a comment, sign in
Joe Schmidt reposted this
Report this post
Direct Biologics

4,149 followers
1y

Exosomes were first described in two papers published within a week of each other 40 years ago, including one co-authored by Dr. Rose Mamelak Johnstone, PhD. She is credited with the discovery that paved the way for our extracellular vesicle (EV)-based regenerative medicine platform. #regenerativemedicine #extracellularvesicles #biotech #drugdiscovery #ulcerativecolitis #ards #crohnsdisease #exosomes
Like Comment
To view or add a comment, sign in
Joe Schmidt

Co-Founder and Member of the Board of Directors
1y
Report this post
Very proud of the great work being done by the entire Direct Biologics team!

Direct Biologics

4,149 followers
1y

Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease ExoFlo is the first extracellular vesicle therapeutic candidate to be evaluated in this indication https://lnkd.in/gPySAYiR #regenerativemedicine #extracellularvesicles #biotech #drugdiscovery #ulcerativecolitis #ARDS #crohnsdisease

3 Comments
Like Comment
To view or add a comment, sign in
Joe Schmidt

Co-Founder and Member of the Board of Directors
1y
Report this post
Very proud of the team at Direct Biologics for reaching yet another major milestone!

Direct Biologics

4,149 followers
1y Edited

Direct Biologics Reports Compelling Data as ExoFlo™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects Company’s Phase 3 EXTINGUISH ARDS trial is enrolling hospitalized patients with moderate-to-severe ARDS regardless of underlying etiology https://lnkd.in/gQkFxe2R #regenerativemedicine #extracellularvesicles #biotech #drugdiscovery #ulcerativecolitis #ARDS #crohnsdisease

2 Comments
Like Comment
To view or add a comment, sign in
Joe Schmidt

Co-Founder and Member of the Board of Directors
1y
Report this post
I’m really proud of our team at Direct Biologics! #innovation #technology #startups https://lnkd.in/gfUfDeRV

Direct Biologics Announces FDA Authorization to Expand Ongoing Phase 3 Clinical Study of ExoFlo™ to All-Cause Moderate-to-Severe ARDS | Direct Biologics

https://directbiologics.com

3 Comments
Like Comment
To view or add a comment, sign in
Joe Schmidt

Co-Founder and Member of the Board of Directors
1y
Report this post
The initiation of our Phase I trial for Crohn’s Disease is an exciting step towards improving the standard of care for challenging IBD conditions.
Direct Biologics

4,149 followers
1y

The Phase 1 clinical trial of our investigational biologic, ExoFlo™, in medically refractory Crohn’s disease is officially underway with the first patient dosed via IV administration. https://lnkd.in/eP2bVi4X #Crohnsdisease #ClinicalTrials
Like Comment
To view or add a comment, sign in
Joe Schmidt

Co-Founder and Member of the Board of Directors
1y
Report this post
We are pleased to share the results from our landmark, Phase II clinical trial of our drug candidate ExoFlo for the treatment of COVID-19 Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS). This represents the first ever prospective, randomized, multicenter, placebo controlled clinical trial for a Bone Marrow Mesenchymal Stem Cell derived Extracellular Vesicle (EV) product. This trial demonstrates safety and appropriate dosing for this indication. We are currently enrolling and look forward to completing our Phase III clinical trial. I want to thank everyone who continues to work diligently to bring our life-saving drug candidate ExoFlo to market, including healthcare providers, the FDA, the Direct Biologics team, our investors and partners. #covid19 #clinicalTrials #innovation
Direct Biologics

4,149 followers
1y

We’re pleased to announce announce favorable safety, dosing and efficacy results from our Phase 2 clinical trial of ExoFlo™, our experimental extracellular vesicle (EV)-based regenerative medicine, in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS). https://lnkd.in/eRr44Cna #Covid-19 #ClinicalTrials
1 Comment
Like Comment
To view or add a comment, sign in
Joe Schmidt

Co-Founder and Member of the Board of Directors
1y
Report this post
Direct Biologics

4,149 followers
1y

Happy International Women’s Day from the Direct Biologics team! As biotech and healthcare innovators, we value diversity, equality, respect, and inclusion at every level. #leadership #regenerativemedicine #biotech #healthcare #InternationalWomensDay #WomenInStem #WomenInScience
Like Comment
To view or add a comment, sign in

3,187 followers

47 Posts

View Profile Follow

Joe Schmidt’s Post

More Relevant Posts

Explore topics